Navigation Links
QualTech Laboratories Validates USP Protocols for Anti-Factor IIa Chromogenic Assay for Potency
Date:8/12/2009

OCEAN, N.J., Aug. 12 /PRNewswire/ -- QualTech Laboratories, Inc., an analytical testing laboratory specializing in biological assays, toxicity studies, and quality control measures, announced today that they have validated the USP (United States Pharmacopeia) method for the anti-factor IIa chromogenic assay for potency. This anti-factor IIa assay is a required component of the newly-revised Heparin Sodium monograph, which becomes effective October 1, 2009.

The Heparin Sodium monograph was revised due to previous contamination which resulted in multiple fatalities. The revisions to the Heparin Sodium monograph improve purity, potency, and identity tests. Among these revisions, the anti-factor IIa assay for potency replaces the previously-used sheep plasma-based clotting assay.

In anticipation of the changes to the Heparin Sodium monograph, QualTech Laboratories began testing the new anti-factor IIa assay protocols in early 2009, and validated the method in March of 2009. Elizabeth Raike, President and CEO of QualTech Laboratories, affirms, "We have validated the anti-factor IIa chromogenic assay according to USP <1225> Validation of Compendial Procedures for accuracy, precision, specificity, linearity, and range. We wanted to be proactive in validating the anti-factor IIa assay so that we could help companies smoothly transition to the requirements of the revised USP Heparin Sodium monograph."

QualTech Laboratories has been performing the anti-factor IIa assay for years according to both EP (European Pharmacopoeia) and BP (British Pharmacopoeia) methods, and therefore offers a wealth of experience to pharmaceutical firms. Additionally, the anti-factor Xa activity test, which is also part of the Heparin Sodium monograph, has been one of QualTech Laboratories' specialties for over 10 years.

"The revisions to the Heparin Sodium monograph were approved very swiftly," Raike notes. "This could cause drug companies significant pressure in their efforts to keep Heparin Sodium on the market. With our validated anti-factor IIa assay method, they don't have to miss a beat - we can keep their drugs in the marketplace and generating revenue."

About QualTech Laboratories, Inc.

QualTech Laboratories, Inc., founded in 1996, specializes in biological assays, toxicity studies, and quality control measures, including menotropins assays (FSH and LH), heparin studies, anti-factor Xa activity testing, anti-factor IIa assays, and bacterial endotoxins testing. QualTech works with USP (United States Pharmacopeia), EP (European Pharmacopoeia), and BP (British Pharmacopoeia) methods and provides all supporting tests for those monographs.

More information about QualTech Laboratories, Inc. is available online at www.QualTechLabsInc.com, by telephone at (732) 918-0207, and via email at eraike@qualtechlabsinc.com.


'/>"/>
SOURCE QualTech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):